I-Mab Biopharma is a Shanghai, China-based company focused on developing innovative biologics in immuno-oncology and immuno-inflammation. Led by founder and CEO Dr. Jingwu Zang, the company emphasizes target biology, antibody engineering, and pre-clinical and clinical development. It has rapidly built a globally competitive pipeline and currently has more than ten investigational drugs under development. I-Mab maintains partnerships with biotech and pharma firms such as Genexine, Ferring Pharmaceuticals and MorphoSys AG, and works with CROs including WuXi Biologics and TigerMed. The company completed a $220M Series C financing and intends to use the proceeds to advance the pre-clinical and clinical development of multiple Best-in-Class and First-in-Class assets.

Total raised

$220M

Funding rounds

1

Latest round

Series C

Latest activity

Jun 2018